The global congenital hyperinsulinism treatment market is expected to garner a market value of USD 100 Million in 2023 and is expected to accumulate a market value of USD 179.08 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Congenital Hyperinsulinism registered a CAGR of 4% in the historical period 2017 to 2022.
Diabetes is a most common health problem causing high blood sugar levels resulting in excessive thirst and large amounts of urine production. It causes secondary health-associated problems such as diabetic ketoacidosis, hyperosmolar hyperglycemic states, and other serious complications (heart attack, stroke, kidney failure, leg amputation) leading to premature death.
The growing number of patients suffering from diabetes will accelerate the market growth rate. Moreover, increasing awareness among physicians and patients about the benefits of Congenital Hyperinsulinism will provide beneficial opportunities for the growth of the Congenital Hyperinsulinism Treatment market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 100 Million |
| Anticipated Forecast Value (2033) | USD 179.08 Million |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Congenital Hyperinsulinism reflected a value of 4% during the historical period, 2017 to 2022. Various factors such as awareness of wellness and health and the rising geriatric population suffering from diabetes are projected to drive the market growth.
In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Congenital Hyperinsulinism treatment is fuelling the market growth. Thus, the market for Congenital Hyperinsulinism is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Strong Relation Between Diabetes & Congenital Hyperinsulinism to push the market growth
The increasing prevalence of Congenital Hyperinsulinism disease is one of the biggest drivers of the market. As per studies, Congenital hyperinsulinism affects approximately 1 in 50,000 newborns. This condition is more common in certain populations, affecting up to 1 in 2,500 newborns.
Furthermore, studies suggest that about 60% of babies with HI are diagnosed during the first month of life. An additional 30% will be diagnosed later in the first year and the remainder after that. With early treatment and aggressive prevention of hypoglycemia, brain damage can be prevented. However, brain damage can occur in children with HI if the condition is not recognized or if treatment is ineffective in the prevention of hypoglycemia.
The massive growth in the diabetic population is primarily attributable to rising Congenital Hyperinsulinism rates around the world, as well as sedentary lifestyles defined by poor diets and decreased physical exercise.
Furthermore, a strong relationship between diabetes and Congenital Hyperinsulinism has been proven by certain studies. For instance, NCBI states that β cell failure in type 2 diabetes (T2D) is associated with hyperglycemia, but the mechanisms are not fully understood. Congenital hyperinsulinism caused by glucokinase mutations (GCK-CHI) is associated with β cell replication and apoptosis. Here, we show that genetic activation of β cell glucokinase, initially triggering replication, causes apoptosis associated with DNA double-strand breaks and activation of the tumor suppressor p53.
Considering these in-depth studies, the market is projected to show considerable growth through 2033.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Congenital Hyperinsulinism, less awareness of Congenital Hyperinsulinism disease, and insubstantial treatment options are hampering the market growth.
Improvement in healthcare spending propelling growth of Congenital Hyperinsulinism in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of Congenital Hyperinsulinism treatment in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the treatment market worldwide.
Technological Advancements Shaping Landscape for Congenital Hyperinsulinism in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospitals to take the lead and drive market growth
The application segment has been divided into hospitals, retail pharmacies, and Ambulatory Surgical Centres. According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during Congenital Hyperinsulinism treatment facilitates the growth of this segment.
Key start-up players in the Congenital Hyperinsulinism Treatment Market are-
Key players in the Congenital Hyperinsulinism Treatment Market are Eli Lilly, Novo Nordisk, Novartis AG, Rezolute, Inc., Eiger BioPharmaceuticals., Zealand Pharma A/S, Hanmi Pharmaceutical Co., Ltd., Crinetics Pharmaceuticals, Inc., AmideBio LLC, and Xeris Pharmaceuticals, Inc.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 100 Million |
| Market Value in 2033 | USD 179.08 Million |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Procedure, Application, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa(MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC Countries, South Africa |
| Key Companies Profiled | Eli Lilly, Novo Nordisk, Novartis AG, Rezolute, Inc., Eiger BioPharmaceuticals., Zealand Pharma A/S, Hanmi Pharmaceutical Co., Ltd., Crinetics Pharmaceuticals, Inc., AmideBio LLC, Xeris Pharmaceuticals, Inc |
| Customization | Available Upon Request |
The congenital hyperinsulinism treatment market CAGR for 2033 is 6%.
The market is estimated to reach USD 179.08 million by 2033.
Key congenital hyperinsulinism treatment market players are introducing new and innovative therapies.
The market is estimated to secure a valuation of USD 100 million in 2023.
Zealand, Rezolute, and Xeris are the three key congenital hyperinsulinism treatment market players.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Methods 5.1. Drug Therapy 5.1.1. Diazoxide 5.1.2. Octreotide 5.1.3. Glucagon 5.1.4. Others 5.2. Surgery 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Hospitals 6.2. Clinics 6.3. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Eli Lilly 15.2. Novo Nordisk 15.3. Novartis AG 15.4. Rezolute, Inc. 15.5. Eiger BioPharmaceuticals 15.6. Zealand Pharma A/S 15.7. Hanmi Pharmaceutical Co., Ltd. 15.8. Crinetics Pharmaceuticals, Inc. 15.9. AmideBio LLC 15.10. Xeris Pharmaceuticals, Inc. 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Congenital Hyperinsulinism Treatment Market
